Alpha-synuclein SAA clinical validation and stratification research program
exploratoryEvaluate alpha-synuclein seed amplification assay performance, longitudinal consistency, genetic subgroup associations, disease subtype prediction, and biomarker relationships across Parkinson's disease, prodromal cohorts, Alzheimer's disease, Lewy body diseases, and multiple system atrophy.
Clinical cohort studies using CSF alpha-synuclein seed amplification assay results, including longitudinal sampling, genotype-defined cohorts, plasma neurofilament light-chain association analysis, and comparison with PET biomarkers or other assay conditions.
Multiple 2026 publications or listed manuscripts report assay consistency, genetic carrier analyses, Alzheimer's disease plasma NfL association, Parkinson's disease subtype prediction, and Lewy body disease versus multiple system atrophy differentiation.
Reported findings include high longitudinal consistency in PPMI participants, association of alpha-synuclein SAA positivity with prodromal PD probability scores in GBA1 carriers and non-carriers, association with increased plasma neurofilament light chain in Alzheimer's disease, and ability of Amprion assay conditions to help separate Lewy body diseases from multiple system atrophy in one study.